Thursday, October 15, 2026

How We Source Explore Search

Via News Knowledge File

Elon Musk

person80% conf.·synced Oct 14, 2026

Entrepreneur known for concentrated portfolio approach

41

sourced metrics

1053

relationships

20

stated objectives

8

Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Net Worth As Pct Of Us Gdp

3percent

Ownership Stake Tesla

10percent

Social Media Post Views

68000000views

Social Media Post Likes

195000likes

Social Media Post Comments

46000comments

Ai Compute Output Worldwide

20gigawatts_per_year

Ownership Stake Spacex

38percent

Voting Power Pct

85percent

Cash

38USD

Voting Control

85percent

Compensation

44.9USD

Compensation Value

1000billion_USD

Market Cap

1000000000000USD

Market Share

42percent

Aug 16, 2026source

Net Worth

1000USD

Jul 27, 2026source

Net Worth Sensitivity Per Dollar Spacex

4.76USD

Jun 23, 2026source

Parameter Count

10votes_per_Class_B_share

Jun 17, 2026source

Shares Owned Spacex

4760000000shares

Jun 1, 2026source

Stated objectives

Get $1 trillion from Tesla

target: 1000000000000 stated

Deliver on promises for Tesla robotaxi and Optimus humanoid robot

stated

Send rockets to Mars regularly before taking SpaceX public (historical objective)

stated

Colonize Mars using SpaceX Starship and associated infrastructure

stated

Reduce the size of the US government so Americans can keep more of their earned income

stated

Reduce the size of the US government so citizens can keep more of their hard-earned money

stated

Increase ownership stake in Tesla to mid-20s percentage for voting control

target: 28 percent by 2034-11-06 00:00:00stated

Deliver transformational performance through operational breakthroughs, innovation, and value creation to earn 2025 CEO Performance Award

target: extraordinary milestones required for any payout stated

Achieve Level 5 autonomy for Tesla vehicles

stated

Own physical assets like real estate and stocks instead of cash during high inflation

stated

Relationship graph · 1053 connections

founded

389

Employs

377

Owns

105

Competes with

26

Covered by

15

lawsuit

14

Developed by

12

Invested in

11

Via News coverage

Adobe's Miss, Alphabet's Squeeze, and an Executive Exodus: The Market Stops Rewarding the AI Story and Starts Asking for Results

September 16, 2026

Google Loosens Its AI Watermark Rules Just as the Industry Claims to Be Tightening Them

August 19, 2026

SPCQ Offers -200% SpaceX Exposure, But Its Daily Reset Punishes Long-Term Bears Globally

NVIDIA Vision Platforms Drive Global Autonomous Deployment as Trucking, Robotics Firms Scale Level 4 Systems

NVIDIA Agent Toolkit Lands Salesforce, Adobe, Atlassian, Siemens Deals as Enterprise AI Goes Autonomous

Autonomous Vehicle Makers Abandon Black-Box AI for Verifiable Systems as Global Road Deaths Hit 2 Million Annually

NVIDIA Builds Global Agent Infrastructure as $1B+ Funding Rounds Signal AI Industry Consolidation

Meta AI Chief LeCun Rejects Tech Elite's Authority Over Global AI Governance

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe

October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,986

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,986 facts checked against source5,375 source documents archived

Query this data → isubstrate.com